Rafferty Asset Management, LLC Editas Medicine, Inc. Transaction History

Rafferty Asset Management, LLC

$28.9 Billion
Q3 2024

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$4.67 - $7.28 $2.98 Million - $4.65 Million	-638,222 Reduced 74.81%	214,892 $1 Million
Q1 2024 May 13, 2024	BUY	$7.03 - $11.07 $3.12 Million - $4.92 Million	444,049 Added 108.55%	853,114 $6.33 Million
Q4 2023 Feb 13, 2024	SELL	$6.25 - $11.11 $954,993 - $1.7 Million	-152,799 Reduced 27.2%	409,065 $4.14 Million
Q3 2023 Nov 13, 2023	SELL	$6.92 - $9.31 $555,862 - $747,844	-80,327 Reduced 12.51%	561,864 $4.38 Million
Q2 2023 Aug 11, 2023	SELL	$6.36 - $11.47 $268,143 - $483,586	-42,161 Reduced 6.16%	642,191 $5.29 Million
Q1 2023 May 11, 2023	SELL	$7.03 - $11.53 $608,798 - $998,498	-86,600 Reduced 11.23%	684,352 $4.96 Million
Q4 2022 Feb 13, 2023	BUY	$8.32 - $13.21 $2.77 Million - $4.4 Million	333,191 Added 76.11%	770,952 $6.84 Million
Q3 2022 Nov 14, 2022	BUY	$12.16 - $19.42 $1.15 Million - $1.84 Million	94,662 Added 27.59%	437,761 $5.36 Million
Q2 2022 Aug 12, 2022	SELL	$9.99 - $21.35 $119,520 - $255,431	-11,964 Reduced 3.37%	343,099 $4.06 Million
Q1 2022 May 13, 2022	BUY	$14.08 - $27.63 $2.44 Million - $4.79 Million	173,292 Added 95.34%	355,063 $6.75 Million
Q4 2021 Feb 10, 2022	BUY	$26.55 - $40.57 $3.57 Million - $5.46 Million	134,623 Added 285.53%	181,771 $4.83 Million
Q3 2021 Nov 10, 2021	SELL	$39.27 - $72.94 $885,931 - $1.65 Million	-22,560 Reduced 32.36%	47,148 $1.94 Million
Q2 2021 Aug 10, 2021	SELL	$31.29 - $56.64 $71,403 - $129,252	-2,282 Reduced 3.17%	69,708 $3.95 Million
Q1 2021 May 10, 2021	BUY	$39.71 - $90.58 $2.26 Million - $5.16 Million	56,935 Added 378.18%	71,990 $3.02 Million
Q4 2020 Feb 10, 2021	SELL	$27.07 - $84.35 $1.38 Million - $4.31 Million	-51,104 Reduced 77.24%	15,055 $1.06 Million
Q3 2020 Nov 13, 2020	BUY	$28.06 - $37.16 $917,141 - $1.21 Million	32,685 Added 97.64%	66,159 $1.86 Million
Q2 2020 Aug 07, 2020	BUY	$18.5 - $34.34 $619,269 - $1.15 Million	33,474 New	33,474 $990,000
Q1 2020 May 15, 2020	SELL	$14.88 - $32.78 $733,033 - $1.61 Million	-49,263 Closed	0 $0
Q4 2019 Feb 10, 2020	SELL	$19.49 - $32.63 $1.28 Million - $2.15 Million	-65,902 Reduced 57.22%	49,263 $1.46 Million
Q3 2019 Nov 14, 2019	SELL	$22.49 - $26.81 $701,418 - $836,150	-31,188 Reduced 21.31%	115,165 $2.62 Million
Q2 2019 Aug 09, 2019	BUY	$20.48 - $27.76 $111,247 - $150,792	5,432 Added 3.85%	146,353 $3.62 Million
Q1 2019 May 15, 2019	BUY	$19.43 - $26.41 $2.74 Million - $3.72 Million	140,921 New	140,921 $3.45 Million

Others Institutions Holding EDIT

# of Institutions

248

Shares Held

57M

Call Options Held

410K

Put Options Held

394K

Black Rock Inc. New York, NY

7.78M
Shares

$10.2 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

6.68M
Shares

$8.75 Million
0.0% of portfolio
Deep Track Capital, LP Greenwich, CT

4.9M
Shares

$6.42 Million
0.62% of portfolio
Israel Englander Millennium Management LLC | New York, Ny

3.35M
Shares

$4.39 Million
0.01% of portfolio
State Street Corp Boston, MA

2.46M
Shares

$3.23 Million
0.0% of portfolio

View Full List

About Editas Medicine, Inc.

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $90M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

More about EDIT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rafferty Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Rafferty Asset Management, LLC with notifications on news.

Account